scholarly journals An in vivo model to study the anti-malaric capacity of plant extracts

2015 ◽  
pp. 35-39
Author(s):  
Misael Chinchilla ◽  
Olga M Guerrero ◽  
Gabriela Abarca ◽  
Mario Barrios ◽  
Oscar Castro
Keyword(s):  
Body Weight ◽  
Survival Time ◽  
Plant Extracts ◽  
Liver Weight ◽  
In Vivo Model

An in vivo model to study lhe antimalarie ctfeet 01' plant extraets is described. White mi ce (25-30g body weight) are lreated subeutaneously with 0.6ml of the diluted extraet stUlling seven days before P. ber¡:heí infeetion: trealmenl eontinlles lIntil death or for 30 days. Simultaneously 0.2ml of the extraet are applied per os stming three days befare infection. In a test 01' the model, treated and non-treated animals differed in body weight, survival time, haematocrite, parnsitemia development, and spleen or liver weight of recent dcad 01' killed mice.

Effect of 5-Fluorouracil Administered at Low Doses on Cytotoxic Properties of Methotrexate in the in vivo Model of Mice L1210 Leukemia; According to the Schedule of Treatment

Pteridines ◽  
1994 ◽  
Vol 5 (2) ◽  
pp. 55-60
Author(s):  
Julita Graczyk
Keyword(s):  
Survival Time ◽  
Leukemic Cells ◽  
In Vivo Model ◽  
Low Doses ◽  
Simultaneous Administration ◽  
L1210 Leukemia ◽  
Lymphoid Leukemia ◽  
Cytotoxic Effects

Summary The study compared antineoplastic effects of combined methotrexate and 5-fluorouracil therapy on LI210 lymphoid leukemia in mice according to the schedule of treatment. Methotrexate was administered at doses of: LOw.. 0.5 LOw. 5-Fluorouracil was administered at doses of: 0.2 LOIO, 0.1 LOw, 0.02 LOro. The parameters characterizing the efficacy of the therapy were survival time of mice inoculated with LI2l0 leukemic cells .. as well as 1151 excretory capacity of mice inoculated with 1251-iododeoxyuridine-Iabelled leukemic cells. It has been observed that the longest survival time of mice with LI210 leukemia is obtained when methotrexate is administered prior to 5-fluorouracil. Reversing the schedule, or simultaneous administration of the drugs results in shorter survival time. despite the administration of 5-fluorouracil at low doses, ineffective on LI210 leukemia in monotherapy. Cytotoxic effects on LI210 leukemic cells labelled with 1151UDR were present only when methotrexate was administered prior to 5-fluorouracil.

scholarly journals An Advanced Orthotopic Ovarian Cancer Model in Mice for Therapeutic Trials

2016 ◽  
Vol 2016 ◽  
pp. 1-4 ◽  
Author(s):  
Ying Zhang ◽  
Li Luo ◽  
Xueling Zheng ◽  
Tinghe Yu
Keyword(s):  
Ovarian Cancer ◽  
Survival Time ◽  
Biological Behavior ◽  
In Vivo Model ◽  
Ovarian Cancer Cells ◽  
Recipient Mouse ◽  
Cancer Model ◽  
Therapeutic Trials ◽  
Tumor Fragment

A nude mouse received subcutaneous injection of human ovarian cancer cells HO-8910PM to form a tumor, and then the tumor fragment was surgically transplanted to the ovary of a recipient mouse to establish an orthotopic cancer model. Tumors occurred in 100% of animals. A mouse displayed an ovarian mass, ascites, intraperitoneal spread, and lung metastasis at natural death. The mean survival time was34.1±17.2days, with median survival time of 28.5 days. The findings indicated that the present mouse model can reflect the biological behavior of advanced human ovarian cancers. This in vivo model can be used to explore therapeutic means against chemoresistance and metastasis, and an effective treatment would prolong the survival time.

scholarly journals In Vivo Antidiabetic Efficacy, Mineral Element Composition, and Qualitative Phytochemistry of the Aqueous Leaf Extracts of Pentas zanzibarica (Klotzsch.) Vatke and Olea europaea subspecies africana (Mill.)

2021 ◽  
Author(s):  
Gervason Apiri Moriasi ◽  
Cromwell Mwiti Kibiti ◽  
Mathew Piero Ngugi
Keyword(s):  
Body Weight ◽  
Elemental Composition ◽  
Plant Extracts ◽  
Leaf Extract ◽  
Absorption Spectrometry ◽  
High Morbidity ◽  
Leaf Extracts ◽  
Aqueous Leaf Extract ◽  
Pharmacologically Active

Abstract Persistent hyperglycaemia is the hallmark of diabetes and is accountable for the devastating complications, which cause high morbidity and mortality. Conventional anti-diabetic agents are only palliative and characterised with limited efficacy, adverse effects, high costs, inaccessibility, prompting the need for better alternatives. Therefore, we investigated the in vivo hypoglycaemic activities, elemental composition, and qualitative phytochemistry of the aqueous leaf extracts of P. zanzibarica and O. europaea subspecies africana as potential sources of affordable, safer, accessible, and potent anti-diabetic therapies. In vivo hypoglycaemic activities of the studied plant extracts were evaluated at three dose levels of 50, 100, and 150 mg/Kg body weight (bw) in Alloxan-induced hyperglycaemic Swiss albino mice. The elemental composition of the plant extracts was analysed using the energy dispersive x-ray fluorescence spectroscopy (EDXRF System) and the atomic absorption spectrometry (AAS). Qualitative phytochemical screening was done following standard procedures. In this study, the aqueous leaf extract of P. zanzibarica, significantly (p<0.05) reduced alloxan-induced hyperglycaemia in mice from 163.26±2.24 mg/dL (at 0h) to 52.12±1.16 mg/dL (at the 4th h) at a dose of 50 mg/Kg body weight, 166.98±1.56 mg/dL (at 0h) to 48.90±1.40 mg/dL (at 4th h) at a dose of 100 mg/Kg body weight, and 168.64±2.96 mg/dL (at 0h) to 42.46±1.80 mg/dL (at 4th h) at a dose of 150 mg/Kg body weight, respectively. Similarly, the aqueous leaf extract of O. europaea subspecies africana significantly (p<0.05) reduced hyperglycaemia from 165.74±3.66 mg/dL (at 0h) to 65.26±1.46 mg/dL (at the 4th h) at a dose of 50 mg/Kg body weight, 158.14±3.49 mg/dL (at 0h) to 53.68±1.48 mg/dL (at the 4th h) at a dose of 100 mg/Kg body weight, and from 161.66±2.19 mg/dL (at 0h) to 44.48±1.35 mg/dL (at the 4th h) at a dose of 150 mg/Kg body weight, respectively Furthermore, the extracts contained chromium (Cr), zinc (Zn), magnesium (Mg), among other elements, and phytochemicals like phenols, flavonoids, and alkaloids, among others. Generally, the studied plant extracts exhibited significant hypoglycaemic efficacy in alloxan-induced hyperglycaemic mice, indicating their antidiabetic potential, and possess pharmacologically active phytochemicals and valuable minerals.

HDAC Inhibitors Lead to Significant Survival Benefit in a Novel Fusion Protein TBLR1-Rarα Induced Murine Promyelocytic Leukemia Model

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 1558-1558 ◽  
Author(s):  
Shouyun Li ◽  
Shuang Liu ◽  
Shuying Chen ◽  
Yirui Chen ◽  
Ying Wang ◽  
...  
Keyword(s):  
Body Weight ◽  
Mouse Model ◽  
Survival Time ◽  
Hdac Inhibitors ◽  
Therapeutic Targets ◽  
Promyelocytic Leukemia ◽  
Leukemia Cells ◽  
Control Group

Abstract Introduction: TBLR1-RARα is the tenth fusion gene of acute promyelocytic leukemia (APL) first identified in a rare case of APL with t(3;17)(q26;q21) chromosomal translocation in our previous study. The characteristics of its basic structure and functions had been clarified in our previous study. In this study, we successfully established a novel TBLR1-RARα leukemia mouse model (TR mouse) which fully recapitulated the most relevant features of human APLs. The therapeutic effects of retinoic acid (ATRA), arsenic trioxide (As2O3), cytarabine (Ara-C) and histone deacetylase inhibitors (HDACi) on TR mice were examined. The differentially expressed genes (DEGs) between TR mice and normal mice were compared to explore the possible mechanisms and better therapeutic targets for this kind of APL. Methods: pMSCV-TBLR1-RARα-Flag-IRES-GFP (MSCV-TR) and pMSCV-IRES-GFP (vehicle) retroviral plasmids were constructed and transfected 293T packaging cells to produce retroviruses. Lin- cells from C57BL/6 mice bone marrow were purified and infected with MSCV-TR and vehicle retroviral supernatant. For in vitro assay, the GFP+ lin- cells sorted and incubated with or without different concentrations of ATRA were analyzed for the differentiation and proliferation capacity by cell morphology, myeloid markers (CD11b and GR-1) and colony formation assay. For the in vivo experiment, GFP+ lin- cells transfected with indicated retroviral vectors were injected intravenously to lethally irradiated C57BL/6 mice to establish an APL mouse model. Cell surface markers were analyzed by flow cytometry. In treatment assays, GFP+ spleen cells from TR leukemia mice were injected intravenously into recipient mice. The mice were randomly separated into groups and received different treatment with ATRA, As2O3, As2O3 in combination with ATRA, Ara-C, Ara-C in combination with ATRA, chidamide and NL101, respectively. The percentage of GFP+ cells in peripheral blood and body weight were measured dynamically. The survival time of every group was recorded and compared. RNA-seq assay was used to identify DEGs between TR mice and normal mice. Results: In vitro assays indicated that TBLR1-RARα could either block the differentiation of HSCs at a relatively early stage or enhanced the clonogenic potential of cells. The TBLR1-RARα leukemia mouse model was successfully established. During the ten-month observational period, 3 out of 15 mice transplanted with TBLR1-RARα expressing cells developed an APL-like disease. Development of leukemia was not observed in any of the mice in control group. All the leukemia mice had a body weight loss as well as splenomegaly and hepatomegaly. The phenotype analysis revealed that the progenitor markers Sca-1, CD34 and C-kit were positive, the myeloid lineage markers Gr-1 and CD11b were also positive, erythroid lineage marker Ter119 was weekly positive, but the lymphatic lineage marker B220, CD3,CD4 and CD8 were all negative. TR mice treated with 1.5-2.5 mg/kg ATRA alone or together with 2.0 mg/kg As2O3 didn't survive longer than that of control group, although in vitro differentiation experiment showed that the leukemia cells were sensitive to ATRA. Leukemic mice receiving Ara-C treatment had a much longer survive time. Surprisingly, HDAC inhibitors (12.5 and 25 mg/kg chidamide and 30 mg/kg NL-101) could significantly prolong the survival time of TR mice. Thousands of DEGs had been identified between TR mice and wild type mice, which were widely involved in multiple pathways and participated in various biological functions. Conclusion: The TBLR1-RARα leukemia mouse model was successfully established for the first time, and its main characteristics were clarified. Although the leukemia cells were sensitive to ATRA in vitro, TR mice didn't benefit from ATRA or As2O3 treatment in vivo. Besides Ara-C, HDAC inhibitors, such as chidamide and NL-101 exhibited potency therapeutic values for TR mice, which provided a new strategy for this kind of refractory APL. What' more, lots of genes that might be related with the process of leukemogenesis and new therapeutic targets for TR leukemia were identified. This model would serve as a versatile tool to study the mechanisms of leukemogenesis and help to design better strategies for APLs in further studies. Disclosures No relevant conflicts of interest to declare.

scholarly journals Evaluation of in vivo Synergistic Hypoglycemic & Hypolipidemic Activity of Ethanolic Extract of Calotropis gigantean Leaves in Combination to Metformin in Alloxan Induced Rats

2019 ◽  
pp. 1-10
Author(s):  
Nisrat Jahan ◽  
Nasreen Akter ◽  
Mosiqur Rahman
Keyword(s):  
Body Weight ◽  
Combination Therapy ◽  
Plant Extract ◽  
Leaf Extract ◽  
Liver Weight ◽  
Diabetic Rats ◽  
Hypolipidemic Activity ◽  
Control Group ◽  
Ethanolic Leaf Extract

Aim: The present study was designed to investigate the antidiabetic & hypolipidemic activity of Calotropis gigantean (Family: Apocynaceae) in alloxan-induced diabetic rat model. Study Design: In vivo study was carried out by ethanolic leaf extract was administered in 250 mg/kg body weight concentration and then subjected to different rats models to authenticate the antidiabetic and hyperlipidimic properties of the plant. Place and Duration of Study: Department of Pharmacy, Southeast University, Banani, Dhaka-1213,Bangladesh within a period of July 2018 to December, 2018. Methodology: Diabetes was induced in rats by an intraperitoneal injection (i.p) of alloxan (100 mg/kg B.W). Ethanolic leaf extract of C. gigantean (250 mg/kg B.W) was administrated orally as a single dose per day to the diabetic rats for 7 days. The negative control group received 0.5 ml of sterile normal saline water orally & positive control group received metformin orally. Synergistic effect of plant was evaluated by combination with 100 mg/kg B.W & 50 mg/kg B.W oral administration of metformin. After 7 days study period, fasting blood glucose, total cholesterol, triglyceride, high-density lipoprotein cholesterol, liver weight & body weight were measured only for diabetic group to observe the effects of diabetes induction. Results: Individual plant extract (250 mg/Kg B.W) & Metformin (100 mg/kg B.W) reduced FBG significantly by 52% (P<0.001) & 55.3% (P<0.001) correspondingly. Metformin (100 mg/kg B.W) potentiated reduction (68%) (P<0.001) when combined to plant extract (250 mg/Kg B.W). Significant dose dependent manner was followed when metformin (50 mg/kg B.W) was combined to plant extract (250 mg/Kg B.W). Our results clearly suggests that C. gigantean exhibit hypoglycemic & hypolipidemic activity with an alteration in body-liver weight. The present study also suggested to develop a combination therapy of extract along with metfromin in different doses to minimize the intake of synthetic drug. Significant reduction of TG, TC were noted by extract (250 mg/kg B.W) with 32.42% (P<0.001) & 41.32% (P<0.001) respectively where standard shown the diminution 43.43% (P<0.05) & 47.21% (P<0.001) respectively as compare to Untreated diabetic rats. 50.21% (P<0.01) & 42.38% (P<0.001) reduction of TG & TC were estimated by C.gigantea extracts (250 mg/kg B.W) when combined with Metformin (100 mg/kg B.W). 34.53% (P<0.05) & 41.54% (P<0.001) reduction of TG & TC by C.gigantea extracts (250 mg/kg B.W) were confirmed when combined to Metformin (50 mg/kg B.W). Combination therapy also has shown synergistic effect in elevation of plasma HDL-cholesterol. Conclusion: The results of the study concluded that C. gigantean have potential antidiabetic and antioxidant properties.

Rosuvastatin reduced brain parasite burden in a chronic toxoplasmosis in vivo model and influenced the neuropathological pattern of ME-49 strain

Parasitology ◽  
2019 ◽  
Vol 147 (3) ◽  
pp. 303-309 ◽  
Author(s):  
L. Nishi ◽  
P. L. Santana ◽  
F. F. Evangelista ◽  
L. F. Beletini ◽  
A. H. Souza ◽  
...  
Keyword(s):  
Body Weight ◽  
Toxoplasma Gondii ◽  
Tissue Injury ◽  
Parasite Burden ◽  
Premature Death ◽  
Parasite Load ◽  
In Vivo Model ◽  
Histopathological Analysis ◽  
Inflammatory Condition

AbstractThis study evaluated the effects of rosuvastatin in vivo on toxoplasmosis chronic infection. Thirty-five Swiss mice were orally infected (ME-49 strain). After 50 days, the mice were separated into five groups: GI – non-infected, GII – infected, GIII – infected and treated with pyrimethamine and sulfadiazine (12.5 + 50 mg kg−1 body weight day−1), GIV and GV – infected and treated with rosuvastatin 10 and 40 mg kg−1 body weight day−1, respectively. After 21 days, we collected blood, liver, lungs, femoral biceps and brain were removed for Toxoplasma gondii DNA quantification by qPCR and histopathological analysis. GIV and GV did not present premature death or clinical changes, and the hepatic enzyme levels were lower compared to GI. Toxoplasma gondii DNA was detected mainly in brain and muscle, but the parasite load was significantly lower in GV compared to GII brains (P < 0.05). Histopathological changes were observed in brains, with T. gondii cysts as well as an inflammatory condition, including necrosis areas in GII and GIII. These data confirm active infection with tissue injury. This inflammatory condition was attenuated in the groups treated with rosuvastatin, especially R40 (GV). Our findings demonstrated the in vivo action of rosuvastatin in reducing cerebral parasitic load and indicate that this drug may interfere in chronic toxoplasmosis.

scholarly journals Effects of zeolite inclusion in aflatoxin B1-contaminated diet on the performance of laying duck

2019 ◽  
Vol 44 (3) ◽  
pp. 277
Author(s):  
I. Sumantri ◽  
H. Herliani ◽  
A. N. Rajibi ◽  
R. Edriantina
Keyword(s):  
Body Weight ◽  
Aflatoxin B1 ◽  
Egg Production ◽  
Liver Weight ◽  
The Body ◽  
Final Body Weight ◽  
Randomized Design ◽  
Commercial Feed ◽  
Feed Control

The researchwas objected to study the effect of zeolite inclusion in aflatoxin B1 (AFB1) contaminated diet on the performance of laying duck. A completely randomized design was adopted in the in vivo experiment that consisted of 4 treatments, namely: (1) commercial feed (Control); (2) AFB1-contaminated feed 70 ppb (AFC); (3) Control + 2% zeolite; and (4) AFC + 2% zeolite. Each treatment had 4 replications with 4 ducks in each replication. A total of 64 eight months-female Alabio duck (Anas platyrinchos Borneo) were used in 28 days of the feeding experiment. Data were analyzed according to the general linear model of SPSS 21.0 statistical software. Results indicated that AFB1 exposure significantly (P<0.05) decreased the body weight of laying duck by 1.12%. Zeolite inclusion could prevent the adverse effect of AFB1 on body weight that increased by 2.95% in AFC+2% zeolite. Treatments had no significant effect on egg production and egg weight (P>0.05). Zeolite inclusion resulted in the highest final body weight whilst AFB1 diet without zeolite resulted in the lowest final body weight (P<0.05). Relative liver weight of duck fedAFC diet was 16.62% and to be 15.4% by zeolite addition in the diet. In conclusion, 2% of zeolite inclusion could reduce the adverse effects of AFB1 exposure on the performance of laying duck.

Effect of extended sleep deprivation on tumor growth in rats

1996 ◽  
Vol 271 (5) ◽  
pp. R1460-R1464 ◽  
Author(s):  
B. M. Bergmann ◽  
A. Rechtschaffen ◽  
M. A. Gilliland ◽  
J. Quintans
Keyword(s):  
Immune Response ◽  
Body Weight ◽  
Tumor Growth ◽  
Sleep Deprivation ◽  
Host Defense ◽  
Tumor Size ◽  
Sleep Time ◽  
In Vivo Model ◽  
Catabolic State

To assess the effect of chronic sleep deprivation on host defense, we observed growth and regression of a subdermal allogenic carcinoma (Walker 256 rat tumor) in rats undergoing 10 days of total sleep deprivation (TSD rats), yoked stimulus control (TSC) rats that were partially sleep deprived, and home cage control (HCC) rats. Tumor size was measured daily. Integrated tumor size was smaller in TSD rats than in both TSC (P = 0.04) and HCC rats (P = 0.0003). Thus host defense against these tumors (as defined by reduction in tumor size) was improved by sleep deprivation. This improvement could be a nonspecific effect, e.g., tumor growth can be inhibited by a catabolic state (dietary restriction). TSD and TSC rats lost body weight, indicating a catabolic state. However, tumor size was not predicted by body weight change, but was predicted by change in sleep time (P = 0.02). Host defense enhancement could alternatively result from enhanced immune response. Early tumor size (5 days) was similar in the three groups, but peaked sooner in TSD rats than in both TSC (P = 0.05) and HCC rats (P = 0.01), leading to large differences in size later. Immune-suppressed rats also showed little difference from HCC rats in early growth but large differences later. Thus host defense in an in vivo model that manifests a systemic immune response can be enhanced by sleep deprivation with timing, which is consistent with an enhancement of the immune response.

scholarly journals Antitrypanosomal Activity of Hydromethanol Extract of Leaves of Cymbopogon Citratus and Seeds of Lepidium Sativum: in-vivo Mice Model

2021 ◽  
Author(s):  
Ayechew Yetayeh Emiru ◽  
Eyasu Makonnen Eshetu ◽  
Fikru Regassa Gari ◽  
Fekadu Regassa Gudeta ◽  
Takele Beyene Tufa
Keyword(s):  
Body Weight ◽  
Plant Extracts ◽  
Field Isolate ◽  
Lepidium Sativum ◽  
Mice Model ◽  
Cymbopogon Citratus ◽  
Cell Counts ◽  
Antitrypanosomal Activity ◽  
Crude Extracts

Abstract Background: Trypanosomiasis is one of the neglected tropical diseases of both humans and animals which decreases their productivity and causes death in the worst scenario. Unavailability of vaccine, low therapeutic index of trypanocidal drugs, and development of resistance lead to the need for research focused on developing alternative treatment options especially from medicinal plants. The present study was aimed to investigate antitrypanosomal activities of leaves of Cymbopogon citratus and seeds of Lepidium sativum in in vivo mice model. Methods: The plant extracts were prepared by maceration using 80% methanol and reconstituted with 10% dimethyl sulfoxide (DMSO) to have the desired concentration. The test doses were adjusted to 100, 200 and 400mg/kg based on the toxicity profile. The Plants extracts were administered to the respective groups of mice after the 12th day of field isolate T. congolense inoculation for seven consecutive days. The level of parasitemia, body weight, packed cell volume, and differential white blood cell counts were measured.Results: The in vivo test results revealed that both plant extracts had dose dependent antitrypanosomal activity. Both crude extracts showed a significant reduction in parasite load (P<0.05), ameliorate anaemia (increased or prevent the fall of PCV value) (P<0.05), decreased lymphocytosis and increased neutrophil counts (p<0.05) and improved body weight but significant body weight increment (P<0.05) was observed only in C. citratus treated mice compared to the negative and positive controls. Comparative results from all tested parameters showed that the best activities were observed with C. citratus treated groups of mice. Conclusion: The present study concluded that the crude extracts of leaves of C. citratus and seeds of L. sativum had antitrypanosomal effects and can be potential targets for further studies on the development of alternative antitrypanosomal agents.

Sign in / Sign up

Export Citation Format

Share Document